Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT

NCT01070030 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01070030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01070030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2010
Completion date
October 31, 2010
Enrollment
230 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii hypertension